The World Health Organization on Saturday urged governments to stock generic GLP-1 medicines and insulin in primary care clinics, using World Diabetes Day to argue that cheaper semaglutide could reach patients in low-income settings. The Geneva-based agency said most people with diabetes still lacked treatment.

The call came as generic semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, spread through markets where patents lapsed this year, including India, Brazil, Canada and China. The WHO added GLP-1 receptor agonists to its Model List of Essential Medicines in September 2025. It issued its first guideline on the drugs for obesity treatment that December.

The agency pointed to research published in The Lancet in November 2024, which estimated that about 828 million adults were living with diabetes. That study, led by the NCD Risk Factor Collaboration, found that roughly 59 per cent of adults over 30 with the condition were not receiving treatment. The International Diabetes Federation, which organises World Diabetes Day, has projected that the number of adults with diabetes will exceed 850 million by 2050.

The International Diabetes Federation said the day's events focused on well-being and access to care, with landmarks in dozens of cities lit blue on Saturday evening. Diabetes UK used the occasion to call for faster access to continuous glucose monitors across the NHS. Health ministries in India and Pakistan announced free screening camps at public hospitals.

Public health researchers have warned that generic GLP-1 drugs alone will not close the treatment gap without trained staff and reliable supply chains. Insulin, discovered more than a century ago, remains unaffordable or unavailable for many patients in sub-Saharan Africa, according to the WHO. World Diabetes Day is held each year on 14 November, the birthday of the insulin co-discoverer Frederick Banting.